{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T16:35:12Z","timestamp":1778776512988,"version":"3.51.4"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T00:00:00Z","timestamp":1551139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"E-DA Hospital","award":["EDAHP101019 & EDAHP102028"],"award-info":[{"award-number":["EDAHP101019 & EDAHP102028"]}]},{"name":"Chi Mei Medical Cancer","award":["CLFHR10307"],"award-info":[{"award-number":["CLFHR10307"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12885-019-5379-9","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T13:05:10Z","timestamp":1551186310000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Zoledronic acid blocks the interaction between breast cancer cells and regulatory T-cells"],"prefix":"10.1186","volume":"19","author":[{"given":"Hsien","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Han","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin-Cheh","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsun-Mei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,26]]},"reference":[{"issue":"14","key":"5379_CR1","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1111\/febs.13656","volume":"283","author":"C Liu","year":"2016","unstructured":"Liu C, Workman CJ, Vignali DA. Targeting regulatory T cells in tumors. FEBS J. 2016;283(14):2731\u201348.","journal-title":"FEBS J"},{"issue":"1","key":"5379_CR2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1111\/j.1365-2249.2012.04657.x","volume":"171","author":"K Oleinika","year":"2013","unstructured":"Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol. 2013;171(1):36\u201345.","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"5379_CR3","doi-asserted-by":"publisher","first-page":"6160","DOI":"10.4049\/jimmunol.0802664","volume":"182","author":"Z Liu","year":"2009","unstructured":"Liu Z, Kim JH, Falo LD Jr, You Z. Tumor regulatory T cells potently abrogate antitumor immunity. J Immunol. 2009;182(10):6160\u20137.","journal-title":"J Immunol"},{"issue":"2","key":"5379_CR4","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.2008.18.7229","volume":"27","author":"P Salama","year":"2009","unstructured":"Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol. 2009;27(2):186\u201392.","journal-title":"J Clin Oncol"},{"issue":"5","key":"5379_CR5","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1158\/0008-5472.CAN-11-2493","volume":"72","author":"LY Chang","year":"2012","unstructured":"Chang LY, Lin YC, Mahalingam J, Huang CT, Chen TW, Kang CW, Peng HM, Chu YY, Chiang JM, Dutta A, et al. Tumor-derived chemokine CCL5 enhances TGF-beta-mediated killing of CD8(+) T cells in colon cancer by T-regulatory cells. Cancer Res. 2012;72(5):1092\u2013102.","journal-title":"Cancer Res"},{"issue":"3","key":"5379_CR6","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1182\/blood-2006-02-002774","volume":"108","author":"M Beyer","year":"2006","unstructured":"Beyer M, Schultze JL. Regulatory T cells in cancer. Blood. 2006;108(3):804\u201311.","journal-title":"Blood"},{"issue":"1","key":"5379_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/CJI.0b013e318189f13c","volume":"32","author":"TA Moo-Young","year":"2009","unstructured":"Moo-Young TA, Larson JW, Belt BA, Tan MC, Hawkins WG, Eberlein TJ, Goedegebuure PS, Linehan DC. Tumor-derived TGF-beta mediates conversion of CD4+Foxp3+ regulatory T cells in a murine model of pancreas cancer. J Immunother. 2009;32(1):12\u201321.","journal-title":"J Immunother"},{"issue":"12","key":"5379_CR8","doi-asserted-by":"publisher","first-page":"5211","DOI":"10.1158\/0008-5472.CAN-05-0141","volume":"65","author":"S Sharma","year":"2005","unstructured":"Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Tumor cyclooxygenase-2\/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer. Cancer Res. 2005;65(12):5211\u201320.","journal-title":"Cancer Res"},{"issue":"10","key":"5379_CR9","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1002\/ijc.23392","volume":"122","author":"Y Mizukami","year":"2008","unstructured":"Mizukami Y, Kono K, Kawaguchi Y, Akaike H, Kamimura K, Sugai H, Fujii H. CCL17 and CCL22 chemokines within tumor microenvironment are related to accumulation of Foxp3+ regulatory T cells in gastric cancer. Int J Cancer. 2008;122(10):2286\u201393.","journal-title":"Int J Cancer"},{"issue":"1","key":"5379_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1158\/0008-5472.CAN-09-2326","volume":"70","author":"ZG Fridlender","year":"2010","unstructured":"Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, et al. CCL2 blockade augments cancer immunotherapy. Cancer Res. 2010;70(1):109\u201318.","journal-title":"Cancer Res"},{"issue":"1","key":"5379_CR11","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s00281-006-0022-7","volume":"28","author":"RF Wang","year":"2006","unstructured":"Wang RF. Regulatory T cells and innate immune regulation in tumor immunity. Springer Semin Immunopathol. 2006;28(1):17\u201323.","journal-title":"Springer Semin Immunopathol"},{"issue":"7","key":"5379_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.humimm.2009.03.012","volume":"70","author":"AM Fietta","year":"2009","unstructured":"Fietta AM, Morosini M, Passadore I, Cascina A, Draghi P, Dore R, Rossi S, Pozzi E, Meloni F. Systemic inflammatory response and downmodulation of peripheral CD25+Foxp3+ T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer. Hum Immunol. 2009;70(7):477\u201386.","journal-title":"Hum Immunol"},{"issue":"5","key":"5379_CR13","doi-asserted-by":"publisher","first-page":"2753","DOI":"10.4049\/jimmunol.0801124","volume":"182","author":"AW Mailloux","year":"2009","unstructured":"Mailloux AW, Young MR. NK-dependent increases in CCL22 secretion selectively recruits regulatory T cells to the tumor microenvironment. J Immunol. 2009;182(5):2753\u201365.","journal-title":"J Immunol"},{"issue":"4","key":"5379_CR14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1097\/01.cji.0000205644.43735.4e","volume":"29","author":"UK Liyanage","year":"2006","unstructured":"Liyanage UK, Goedegebuure PS, Moore TT, Viehl CT, Moo-Young TA, Larson JW, Frey DM, Ehlers JP, Eberlein TJ, Linehan DC. Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinoma. J Immunother. 2006;29(4):416\u201324.","journal-title":"J Immunother"},{"issue":"1","key":"5379_CR15","doi-asserted-by":"publisher","first-page":"261","DOI":"10.2147\/TCRM.S2707","volume":"4","author":"TJ Polascik","year":"2008","unstructured":"Polascik TJ, Mouraviev V. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag. 2008;4(1):261\u20138.","journal-title":"Ther Clin Risk Manag"},{"issue":"1","key":"5379_CR16","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1097\/FPC.0b013e328335729c","volume":"21","author":"L Gong","year":"2011","unstructured":"Gong L, Altman RB, Klein TE. Bisphosphonates pathway. Pharmacogenet Genomics. 2011;21(1):50\u20133.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"5379_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jbo.2013.12.001","volume":"3","author":"J Zekri","year":"2014","unstructured":"Zekri J, Mansour M, Karim SM. The anti-tumour effects of zoledronic acid. J Bone Oncol. 2014;3(1):25\u201335.","journal-title":"J Bone Oncol"},{"issue":"2","key":"5379_CR18","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1093\/annonc\/mdu544","volume":"26","author":"M Gnant","year":"2015","unstructured":"Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radisic V, et al. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian breast and colorectal Cancer study group trial 12. Ann Oncol. 2015;26(2):313\u201320.","journal-title":"Ann Oncol"},{"issue":"2","key":"5379_CR19","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mds277","volume":"24","author":"R Coleman","year":"2013","unstructured":"Coleman R, de Boer R, Eidtmann H, Llombart A, Davidson N, Neven P, von Minckwitz G, Sleeboom HP, Forbes J, Barrios C, et al. Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results. Ann Oncol. 2013;24(2):398\u2013405.","journal-title":"Ann Oncol"},{"issue":"9","key":"5379_CR20","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","volume":"15","author":"R Coleman","year":"2014","unstructured":"Coleman R, Cameron D, Dodwell D, Bell R, Wilson C, Rathbone E, Keane M, Gil M, Burkinshaw R, Grieve R, et al. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol. 2014;15(9):997\u20131006.","journal-title":"Lancet Oncol"},{"issue":"8","key":"5379_CR21","first-page":"2893","volume":"9","author":"D Santini","year":"2003","unstructured":"Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Battistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V, et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2003;9(8):2893\u20137.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"5379_CR22","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.4049\/jimmunol.1002514","volume":"187","author":"B Castella","year":"2011","unstructured":"Castella B, Riganti C, Fiore F, Pantaleoni F, Canepari ME, Peola S, Foglietta M, Palumbo A, Bosia A, Coscia M, et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vgamma9Vdelta2 T cells, alphabeta CD8+ T cells, regulatory T cells, and dendritic cells. J Immunol. 2011;187(4):1578\u201390.","journal-title":"J Immunol"},{"issue":"12","key":"5379_CR23","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1111\/j.1582-4934.2009.00926.x","volume":"14","author":"M Coscia","year":"2010","unstructured":"Coscia M, Quaglino E, Iezzi M, Curcio C, Pantaleoni F, Riganti C, Holen I, Monkkonen H, Boccadoro M, Forni G, et al. Zoledronic acid repolarizes tumour-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway. J Cell Mol Med. 2010;14(12):2803\u201315.","journal-title":"J Cell Mol Med"},{"issue":"7","key":"5379_CR24","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1002\/jbmr.37","volume":"25","author":"T Kikuiri","year":"2010","unstructured":"Kikuiri T, Kim I, Yamaza T, Akiyama K, Zhang Q, Li Y, Chen C, Chen W, Wang S, Le AD, et al. Cell-based immunotherapy with mesenchymal stem cells cures bisphosphonate-related osteonecrosis of the jaw-like disease in mice. J Bone Miner Res. 2010;25(7):1668\u201379.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"5379_CR25","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1089\/jir.2005.25.20","volume":"25","author":"CM Robinson","year":"2005","unstructured":"Robinson CM, Hale PT, Carlin JM. The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase. J Interf Cytokine Res. 2005;25(1):20\u201330.","journal-title":"J Interf Cytokine Res"},{"issue":"1","key":"5379_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s12865-016-0183-7","volume":"17","author":"H Liu","year":"2016","unstructured":"Liu H, Wang SH, Chen SC, Chen CY, Lo JL, Lin TM. Immune modulation of CD4+CD25+ regulatory T cells by zoledronic acid. BMC Immunol. 2016;17(1):45.","journal-title":"BMC Immunol"},{"issue":"21","key":"5379_CR27","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.1038\/onc.2016.458","volume":"36","author":"X Wang","year":"2017","unstructured":"Wang X, Lang M, Zhao T, Feng X, Zheng C, Huang C, Hao J, Dong J, Luo L, Li X, et al. Cancer-FOXP3 directly activated CCL5 to recruit FOXP3(+)Treg cells in pancreatic ductal adenocarcinoma. Oncogene. 2017;36(21):3048\u201358.","journal-title":"Oncogene"},{"issue":"19","key":"5379_CR28","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1158\/0008-5472.CAN-11-0573","volume":"71","author":"J Faget","year":"2011","unstructured":"Faget J, Biota C, Bachelot T, Gobert M, Treilleux I, Goutagny N, Durand I, Leon-Goddard S, Blay JY, Caux C, et al. Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. Cancer Res. 2011;71(19):6143\u201352.","journal-title":"Cancer Res"},{"issue":"25","key":"5379_CR29","doi-asserted-by":"crossref","first-page":"37714","DOI":"10.18632\/oncotarget.9265","volume":"7","author":"W Sun","year":"2016","unstructured":"Sun W, Li WJ, Wei FQ, Wong TS, Lei WB, Zhu XL, Li J, Wen WP. Blockade of MCP-1\/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma. Oncotarget. 2016;7(25):37714\u201327.","journal-title":"Oncotarget"},{"issue":"1","key":"5379_CR30","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1475-2867-12-48","volume":"12","author":"T Ibrahim","year":"2012","unstructured":"Ibrahim T, Mercatali L, Sacanna E, Tesei A, Carloni S, Ulivi P, Liverani C, Fabbri F, Zanoni M, Zoli W, et al. Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid. Cancer Cell Int. 2012;12(1):48.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"5379_CR31","doi-asserted-by":"publisher","first-page":"118","DOI":"10.18632\/oncotarget.9497","volume":"8","author":"G Comito","year":"2017","unstructured":"Comito G, Pons Segura C, Taddei ML, Lanciotti M, Serni S, Morandi A, Chiarugi P, Giannoni E. Zoledronic acid impairs stromal reactivity by inhibiting M2-macrophages polarization and prostate cancer-associated fibroblasts. Oncotarget. 2017;8(1):118\u201332.","journal-title":"Oncotarget"},{"issue":"12","key":"5379_CR32","doi-asserted-by":"publisher","first-page":"3623","DOI":"10.1172\/JCI25947","volume":"115","author":"J Dannull","year":"2005","unstructured":"Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, Zhang A, Dahm P, Chao N, Gilboa E, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115(12):3623\u201333.","journal-title":"J Clin Invest"},{"key":"5379_CR33","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1111\/j.1749-6632.2009.04939.x","volume":"1174","author":"AJ Rech","year":"2009","unstructured":"Rech AJ, Vonderheide RH. Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci. 2009;1174:99\u2013106.","journal-title":"Ann N Y Acad Sci"},{"issue":"2","key":"5379_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.cell.2006.05.042","volume":"126","author":"Y Wu","year":"2006","unstructured":"Wu Y, Borde M, Heissmeyer V, Feuerer M, Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell. 2006;126(2):375\u201387.","journal-title":"Cell"},{"issue":"7","key":"5379_CR35","doi-asserted-by":"publisher","first-page":"4376","DOI":"10.4049\/jimmunol.177.7.4376","volume":"177","author":"S Read","year":"2006","unstructured":"Read S, Greenwald R, Izcue A, Robinson N, Mandelbrot D, Francisco L, Sharpe AH, Powrie F. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol. 2006;177(7):4376\u201383.","journal-title":"J Immunol"},{"issue":"12","key":"5379_CR36","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.4049\/jimmunol.1401936","volume":"194","author":"HJ Park","year":"2015","unstructured":"Park HJ, Park JS, Jeong YH, Son J, Ban YH, Lee BH, Chen L, Chang J, Chung DH, Choi I, et al. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells. J Immunol. 2015;194(12):5801\u201311.","journal-title":"J Immunol"},{"issue":"10","key":"5379_CR37","doi-asserted-by":"publisher","first-page":"6079","DOI":"10.4049\/jimmunol.0711823","volume":"182","author":"T Totsuka","year":"2009","unstructured":"Totsuka T, Kanai T, Nemoto Y, Tomita T, Okamoto R, Tsuchiya K, Nakamura T, Sakamoto N, Akiba H, Okumura K, et al. RANK-RANKL signaling pathway is critically involved in the function of CD4+CD25+ regulatory T cells in chronic colitis. J Immunol. 2009;182(10):6079\u201387.","journal-title":"J Immunol"},{"issue":"2","key":"5379_CR38","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.18632\/oncotarget.2731","volume":"6","author":"IC Salaroglio","year":"2015","unstructured":"Salaroglio IC, Campia I, Kopecka J, Gazzano E, Orecchia S, Ghigo D, Riganti C. Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma. Oncotarget. 2015;6(2):1128\u201342.","journal-title":"Oncotarget"},{"issue":"24","key":"5379_CR39","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","volume":"77","author":"GC Prendergast","year":"2017","unstructured":"Prendergast GC, Malachowski WP, DuHadaway JB, Muller AJ. Discovery of IDO1 inhibitors: from bench to bedside. Cancer Res. 2017;77(24):6795\u2013811.","journal-title":"Cancer Res"},{"key":"5379_CR40","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12885-015-1066-7","volume":"15","author":"C Wilson","year":"2015","unstructured":"Wilson C, Ottewell P, Coleman RE, Holen I. The differential anti-tumour effects of zoledronic acid in breast cancer - evidence for a role of the activin signaling pathway. BMC Cancer. 2015;15:55.","journal-title":"BMC Cancer"},{"issue":"13","key":"5379_CR41","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1158\/0008-5472.CAN-10-3862","volume":"71","author":"I Benzaid","year":"2011","unstructured":"Benzaid I, Monkkonen H, Stresing V, Bonnelye E, Green J, Monkkonen J, Touraine JL, Clezardin P. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res. 2011;71(13):4562\u201372.","journal-title":"Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5379-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-019-5379-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-019-5379-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,28]],"date-time":"2020-11-28T16:30:22Z","timestamp":1606581022000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-019-5379-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,26]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["5379"],"URL":"https:\/\/doi.org\/10.1186\/s12885-019-5379-9","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,26]]},"assertion":[{"value":"9 October 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Institutional Review Committee of E-DA Hospital, and the volunteer donors of Treg cells provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"176"}}